Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. Following Global Pharma Review

Related MRK
Markets Little Changed Ahead Of The Federal Reserve's Policy Decision
Earnings Expectations For The Week Of July 28: Exxon, Pfizer, Twitter And Much More
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Merck & Co. (NYSE: MRK), and raised the price target from $54.00 to $56.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Merck & Co. closed on Thursday at $48.73.

Posted-In: Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (MRK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters